CASRAI Dictionary

Tag: public health service policies on research misconduct

  • Duke Research Misconduct Policy vs MIT, Stanford

    Duke, MIT and Stanford each operationalise the same federal research-misconduct standard through different institutional machinery. Duke routes allegations to a Misconduct Review Officer and a 24-hour Integrity Line; MIT centralises review under its Vice President for Research; Stanford assigns first-line assessment to school deans under a Research Policy Handbook chapter revised effective 1 January 2026. All three exist to satisfy one governing rule: the Public Health Service Policy on Research Misconduct.

    The federal policy on research misconduct — codified at 42 C.F.R. Part 93 and enforced by the HHS Office of Research Integrity (ORI) — defines research misconduct as fabrication, falsification, or plagiarism (FFP) in proposing, performing, or reviewing research, or in reporting research results. Every US university that accepts Public Health Service funding, including Duke, MIT and Stanford, must maintain an institutional policy that meets this baseline, then layers its own governance, reporting channels, and disciplinary structure on top.

    How does Duke’s research misconduct policy define and handle allegations?

    Duke’s research misconduct policy is set out in the Duke University Policy and Procedures Governing Misconduct in Research, part of the Faculty Handbook and last updated in May 2023. Allegations are directed to a designated Misconduct Review Officer (MRO), or to a department chair, division chief, or dean, who must promptly forward the matter to the MRO.

    Duke also operates an Integrity Line — a 24-hour, anonymous telephone hotline (1-800-826-8109) — so that reporters can raise concerns without disclosing their identity. This dual-channel design (a named institutional officer plus an anonymous hotline) reflects a broader reform effort: Duke’s policy was revised to extend coverage beyond faculty to research staff, alongside wider research-integrity reforms following a 2019 case in which the university agreed to a $112.5 million False Claims Act settlement over fabricated data in federally funded pulmonary research, as reported by Science. That episode is a documented driver of the university folding staff explicitly into the policy’s scope, according to case-study materials prepared for the Council on Governmental Relations (COGR).

    How does MIT structure its research misconduct procedures?

    MIT’s framework sits in MIT Policies and Procedures §10.1, “Procedures for Dealing with Misconduct in Research and Scholarship,” last updated 10 December 2025. Oversight is centralised: every allegation, wherever it is first raised, must be conveyed promptly to the Vice President for Research (VPR), MIT’s designated Research Integrity Officer.

    MIT’s definition tracks the federal FFP triad — fabrication (making up data), falsification (manipulating materials or altering results), and plagiarism (appropriating another’s ideas or words without credit) — but adds a fourth category not found in the core PHS definition: deliberate interference, meaning intentionally causing material harm to another’s research, such as damaging equipment or deleting data. MIT’s policy also explicitly excludes self-plagiarism (text recycling) and authorship or credit disputes among former collaborators from the definition of misconduct, mirroring longstanding ORI guidance on plagiarism.

    What changed in Stanford’s research misconduct policy for 2026?

    Stanford’s governing chapter, Research Policy Handbook (RPH) 1.7, “Research Misconduct: Policy on Allegations, Investigations, and Reporting,” dates originally to 3 February 1983 but carries a current version effective 1 January 2026. The update aligns Stanford’s procedures with the 2024 Final Rule amending 42 C.F.R. Part 93 — the same federal regulation that governs Duke and MIT.

    Two provisions distinguish Stanford’s approach. First, the “Six-Year Rule” (42 C.F.R. §93.104): research misconduct allegations are only actionable if the conduct occurred within six years of the date Stanford or a federal agency received the allegation, subject to a “subsequent use” exception (if the respondent later cited or republished the disputed material) and a “public health and safety” exception. Second, first-line responsibility sits with the school dean, who must assess an allegation and, if it meets the definition, immediately open an inquiry and notify the Dean of Research — a more devolved structure than MIT’s single VPR intake point.

    How do Duke, MIT and Stanford compare side by side?

    The table below sets the three institutional policies against each other and against the federal baseline they all must satisfy.

    Institution Governing document First-line authority Reporting channel Misconduct definition
    Duke University Policy and Procedures Governing Misconduct in Research (Faculty Handbook, updated May 2023) Misconduct Review Officer MRO, department chair/dean, or anonymous Integrity Line FFP, per 42 C.F.R. Part 93; covers faculty and staff
    MIT MIT Policies and Procedures §10.1 (updated 10 Dec 2025) Vice President for Research Report to VPR, typically via supervisor or department head FFP plus deliberate interference; excludes self-plagiarism and authorship disputes
    Stanford University Research Policy Handbook 1.7 (current version 1 Jan 2026; original 1983) School dean, then Dean of Research Report to school dean for initial assessment FFP per 42 C.F.R. Part 93 (2024 Final Rule); six-year time limitation
    Federal baseline PHS Policy on Research Misconduct, 42 C.F.R. Part 93 HHS Office of Research Integrity (ORI) Institutional report to ORI after a finding Fabrication, falsification, or plagiarism (FFP)

    All three institutions converge on the same two-stage process required by federal policy:

    • An inquiry — a preliminary assessment of whether an allegation has substance and warrants formal review.
    • An investigation — a full evidentiary examination that produces findings reported to ORI when federal funding is involved.

    Common questions on federal and institutional research misconduct policy

    What is the US federal research misconduct policy?

    The US federal research misconduct policy is the Public Health Service Policy on Research Misconduct, codified at 42 C.F.R. Part 93 and enforced by ORI. It applies to fabrication, falsification, and plagiarism in proposing, performing, reviewing, or reporting PHS-supported research, and requires every recipient institution to maintain a compliant local policy.

    What is 42 CFR Part 93 research misconduct?

    42 C.F.R. Part 93 is the federal regulation setting the definitions, procedural standards, and reporting obligations that PHS-funded institutions — including Duke, MIT, and Stanford — must follow. A 2024 Final Rule to Part 93 took effect on 1 January 2026, updating provisions including the definition of plagiarism that institutions must now apply.

    What are the three types of research misconduct?

    The three federally recognised types are fabrication (inventing data or results), falsification (manipulating materials, equipment, or data so the research record is inaccurate), and plagiarism (using another’s ideas, processes, or words without credit). Honest error and legitimate differences of scientific opinion are explicitly excluded.

    What constitutes research misconduct according to federal regulations?

    A federal finding requires three elements together: a significant departure from accepted research practices, conduct committed intentionally, knowingly, or recklessly, and an allegation proven by a preponderance of the evidence. All three tests must be met before ORI or an institution can record a formal finding of misconduct.

    What this means for research administrators

    For research administrators, compliance officers, and institutional leaders, the practical lesson is that federal alignment does not mean procedural uniformity. Duke, MIT, and Stanford each satisfy 42 C.F.R. Part 93, yet route allegations through different first-line authorities — an MRO, a VPR, and a school dean respectively — and set different scope boundaries around staff coverage, deliberate interference, and time limitations. Institutions benchmarking their own research administration policy against peer practice should treat the federal rule as the floor, not the template, and expect further local revisions as the 2024 Final Rule to Part 93 continues to work through university policy cycles into 2026 and beyond.

    Given that Stanford’s update took effect only this year and MIT revised its procedures in December 2025, institutional research misconduct policies are clearly still catching up to the federal 2024 Final Rule — administrators reviewing their own institution’s policy should confirm which version of 42 C.F.R. Part 93 it currently cites before assuming compliance.

  • Research Misconduct Federal Funding: Grant Risk

    When an allegation of research misconduct is opened against a federally funded project, the grant does not simply continue as normal. The funding agency can defer draw-downs, restrict how funds are spent, or suspend the award outright, while the awardee institution — not the agency — conducts the inquiry and investigation under research misconduct federal funding rules that require prompt notification, safeguarding of funds, and, if misconduct is confirmed, cost recovery or debarment.

    Research misconduct is fabrication, falsification, or plagiarism in proposing, performing, or reviewing federally funded research, or in reporting its results — a definition set by the Office of Science and Technology Policy’s 2000 Federal Policy on Research Misconduct (65 Fed. Reg. 76,260) and applied by every major federal research funder.

    What Is Research Misconduct Under Federal Policy?

    Federal research misconduct policy applies a single, government-wide standard: fabrication, falsification, or plagiarism (FFP) committed in proposing, performing, or reviewing federally funded research, or in reporting its results. Under the OSTP Federal Policy on Research Misconduct, a finding requires proof that the conduct represents “a significant departure from accepted practices,” was committed “intentionally, or knowingly, or recklessly,” and is established “by a preponderance of the evidence” — a civil, not criminal, standard.

    Honest error and legitimate differences of scientific opinion are explicitly excluded. The policy also does not cover authorship disputes, harassment, or general grant-management violations, which fall under separate institutional or agency processes.

    • Fabrication — making up data or results and recording or reporting them.
    • Falsification — manipulating materials, equipment, or data so the research record is not accurately represented.
    • Plagiarism — appropriating another person’s ideas, processes, results, or words without credit.

    What Happens to Grant Funds During an Investigation?

    A grant under a misconduct inquiry does not automatically stop, but the funding agency retains authority to take interim administrative actions to protect federal funds while the institution investigates. These typically include deferring decisions on continued funding, restricting the purposes for which existing funds may be spent, requiring special award certifications, or — where the risk is severe — suspending the active award pending outcome.

    Responsibility for the investigation sits primarily with the recipient institution, not the funder. Under Public Health Service (PHS) rules governing NIH-funded research (42 CFR Part 93), and the parallel National Science Foundation framework (45 CFR Part 689), the institution runs its own inquiry and investigation while the agency monitors, can intervene, and controls the purse strings throughout.

    Investigation stage Typical fund status Who acts
    Institutional assessment / inquiry Funds usually continue; agency may be informed Research Integrity Officer (RIO)
    Formal investigation opened Agency may defer, restrict, or condition funding Institution investigates; ORI or NSF OIG notified
    Investigation concluded, misconduct found Suspension, termination, or debarment possible Agency Inspector General / Deciding Official

    Who Must Notify the Funding Agency, and When?

    Every institution receiving PHS or NSF funding is required, as a condition of its funding assurance, to notify the relevant federal office once a formal investigation is opened. For NIH and other Public Health Service awards, that notice goes to HHS’s Office of Research Integrity (ORI); for NSF awards, it goes to the NSF Office of Inspector General (OIG).

    Notification cannot wait for the case to close. If the institution determines during an inquiry or investigation that public health or safety is at risk, that federal interests or resources are threatened, that research activities should be suspended, or that there is a reasonable indication of a possible civil or criminal law violation, it must notify the agency immediately — not at the standard reporting milestones.

    • Immediate notice — health/safety risk, threat to federal resources, or suspected civil/criminal violation.
    • Formal notice at investigation opening — required under the institution’s PHS or NSF assurance.
    • Closing report — the full institutional record, transmitted to ORI or NSF OIG after a final misconduct determination and any institutional appeal.

    What Are the Consequences If Misconduct Is Confirmed?

    If an investigation substantiates research misconduct, the funding agency can impose administrative sanctions independent of, and in addition to, any action the institution itself takes. Under ORI’s guidance on federal policy, “the Federal Government can debar researchers who commit misconduct from receiving Federal funds for a specified period of time,” and institutions commonly pursue their own parallel actions such as termination of employment or mandated supervision of future work.

    Available federal administrative actions include:

    • Correction of the published research record and retraction of affected papers.
    • Letters of reprimand or special certification requirements on future awards.
    • Suspension or termination of the active award, with recovery of misspent federal funds.
    • Suspension or debarment from federal funding, published on the General Services Administration’s SAM.gov exclusions list.
    • Referral to the Department of Justice where civil or criminal fraud is suspected.

    Cost recovery is a distinct lever from debarment: an institution can be required to repay funds tied to fabricated or falsified data even where an individual researcher, not the institution, is the primary respondent.

    How Does the 2024 Final Rule Change the Process?

    The compliance landscape shifted materially with HHS’s Final Rule updating 42 CFR Part 93, published in the Federal Register on 17 September 2024 and formally titled “Public Health Service Policies on Research Misconduct.” The rule took effect 1 January 2025, but institutions were required to apply its new procedural requirements to any allegation received on or after 1 January 2026, with updated institutional policies due to ORI no later than the annual report covering 2025 (filed by 30 April 2026).

    The Final Rule extends two of the timelines research administrators rely on most:

    • Inquiry period: extended from 60 days under the 2005 regulation to 90 days.
    • Investigation period: extended from 120 days under the 2005 regulation to 180 days.

    It also formalises a new pre-inquiry “institutional assessment” stage (§93.306), in which the Research Integrity Officer must document whether an allegation falls within the misconduct definition and PHS jurisdiction before an inquiry is opened — with no fixed time limit for this new stage. The rule further clarifies confidentiality obligations, allowing institutions to disclose respondent identities to journals, co-authors, and collaborating institutions where there is a legitimate need to know, and expands provisions covering multiple respondents and multi-institution proceedings.

    Frequently Asked Questions

    Does the Funding Agency Investigate Misconduct Directly, or Does the Institution?

    The institution conducts the initial inquiry and investigation, not the federal funding agency. Agencies such as ORI or the NSF OIG monitor the case, can intervene if the institution is unable or unwilling to act, and retain authority over the grant throughout.

    What Standard of Proof Applies to a Misconduct Finding?

    A finding requires proof “by a preponderance of the evidence” — more likely than not — not the criminal “beyond a reasonable doubt” standard. The conduct must also be shown to have been committed intentionally, knowingly, or recklessly, and to represent a significant departure from accepted research practice.

    What Is the First Phase of a Research Misconduct Response?

    The process begins with an institutional assessment or inquiry — a preliminary review to decide whether an allegation has enough substance to warrant a full investigation. Under the 2024 Final Rule, this assessment stage is now formally documented before any inquiry clock starts running.

    To Whom Does the Federal Research Misconduct Policy Apply?

    The policy applies to anyone proposing, performing, or reviewing federally funded research — including applicants, grant recipients, subrecipients, project participants, and peer reviewers — at any institution receiving Public Health Service or comparable federal research funding.

    Implications for Research Administrators

    The practical exposure is threefold: a live award can be frozen or restricted mid-project, cost recovery can claw back funds already spent, and delayed or incomplete notification to the funder is a compliance failure in its own right, separate from the underlying allegation. Research integrity offices should treat the 2026 compliance deadline as a trigger to audit their policies against the extended 90/180-day timelines and the new institutional-assessment stage — a policy still reflecting the 2005 regulation’s 60/120-day clock no longer matches what ORI expects in an institutional record.

    The Final Rule’s added reporting elements — sequestration inventories, interview transcripts, and multi-institution coordination — point toward longer, more paperwork-intensive proceedings even as deadlines extend. For anyone administering federally funded research, what happens to the grant while a case runs is as important as the underlying definition of misconduct itself.

  • ORI Research Misconduct Policy: 2026 Annual Assurance Renewal Explained

    The ORI research misconduct policy that governs Public Health Service (PHS)-funded research changed materially for 2026, and the annual paperwork cycle that keeps an institution’s assurance active has not paused to accommodate the transition. Every institution that holds a PHS assurance under 42 CFR Part 93 — whether or not it has an open case — must file its Annual Report on Possible Research Misconduct between 1 January and 30 April 2026, and for the first time that filing sits alongside a revised regulatory framework institutions are expected to have already adopted.

    This is a mechanics piece, not a restatement of the Final Rule’s substance. It sets out exactly what the U.S. Department of Health and Human Services’ Office of Research Integrity (ORI) expects institutions to submit for the 2026 assurance renewal cycle, which form to use, and where the transition from the 2005 regulation creates procedural traps for research integrity officers (RIOs) and sponsored-programs staff.

    What changed: the Final Rule and the 2026 effective date

    ORI’s revised Public Health Service Policies on Research Misconduct — published in the Federal Register on 17 September 2024 and codified at 42 CFR Part 93 — took effect on 1 January 2026. It is the first substantive rewrite of the misconduct regulation since 2005, and it introduces more than twenty-five newly defined terms, including “institutional record,” “administrative record,” “intentionally,” and “recklessly,” aimed at tightening consistency across institutional proceedings.

    The core three-part definition of research misconduct is unchanged: fabrication, falsification, or plagiarism (FFP) that represents a significant departure from accepted practices of the relevant research community, committed intentionally, knowingly, or recklessly, and proven by a preponderance of the evidence. What has changed is procedural detail — respondent comment rights on draft investigation reports, record-retention protocols, and interim-action notification triggers are now spelled out in greater depth.

    Critically, the Final Rule is not retroactive. Allegations received before 1 January 2026 continue to be handled under the 2005 version of Part 93 unless the institution and the respondent agree in writing to proceed under the new rule. Institutions running dual-track proceedings across the transition need to document, case by case, which regulatory version applies.

    Who must file an assurance renewal, and via which form

    Any institution that receives PHS-supported research funds — including awards from NIH, CDC, FDA, HRSA, and other PHS agencies — must maintain an active research misconduct assurance with ORI. Once an assurance is established, the institution is obligated to file annually, regardless of whether it received any misconduct allegations that year.

    • Form: Annual Report on Possible Research Misconduct, Form PHS-6349, submitted through ORI’s online Annual Report system (ARPRM).
    • Filing window: 1 January through 30 April each calendar year, covering the prior calendar year’s activity.
    • 2026 deadline: 30 April 2026, covering the reporting period 1 January–31 December 2025.
    • No-activity institutions: institutions with no PHS-supported research or no allegations in the reporting period may still owe a report; small or inactive institutions should confirm with ORI’s Assurance Program whether a Small Institution or no-activity statement applies to their circumstances.
    • Access: ORI’s Annual Report system now requires two-factor authentication (2FA) — institutions should confirm their registered email with the Assurance Program ([email protected]) well before the deadline to avoid last-minute access issues.

    The 2026 assurance renewal checklist

    Beyond the Form PHS-6349 filing itself, 2026 is unusual because institutions are also expected to have brought their internal policies and procedures into alignment with the new 42 CFR Part 93 requirements. ORI published a Sample Policies and Procedures document in June 2025 specifically to help research integrity officers, compliance staff, and institutional counsel update their templates ahead of the 1 January 2026 effective date.

    Item 2005 rule (pre-2026 cases) 2026 Final Rule
    Effective date 16 June 2005 1 January 2026
    Defined terms in 42 CFR Part 93 Baseline set 25+ additional defined terms
    Applies to allegations received Before 1 Jan 2026 (default) From 1 Jan 2026 onward, or earlier by written agreement
    Annual Report on Possible Research Misconduct Form PHS-6349, Jan–Apr window Unchanged: Form PHS-6349, Jan–Apr window
    Institutional policy alignment N/A Sample Policies and Procedures released June 2025

    Institutions preparing their 2026 renewal should treat the filing as a two-part exercise: (1) submit Form PHS-6349 through ARPRM by 30 April 2026 for the 2025 reporting year, and (2) confirm that the policies and procedures referenced in that assurance actually reflect the post-1-January-2026 regulatory text, not the 2005 language many institutional websites still carry. ORI’s own research administration compliance guidance and case-summary archive remain useful references for RIOs benchmarking their inquiry and investigation timelines against the 60-day inquiry and 120-day investigation targets that persist in the revised rule.

    Frequently asked questions

    What is the deadline for the ORI 2026 annual assurance renewal?

    Institutions holding a PHS research misconduct assurance must file the Annual Report on Possible Research Misconduct (Form PHS-6349) between 1 January and 30 April 2026, covering research misconduct activity from the 2025 calendar year, via ORI’s online ARPRM system.

    Which institutions must maintain an ORI research misconduct assurance?

    Any institution receiving Public Health Service-supported research funds — from NIH, CDC, FDA, or other PHS agencies — must hold an active assurance under 42 CFR Part 93 and file annually, even in years with no reported allegations.

    Does the new ORI Final Rule apply retroactively to open cases?

    No. Allegations received before 1 January 2026 are handled under the 2005 version of 42 CFR Part 93 by default, unless the institution and respondent agree in writing to proceed under the revised rule instead.

    What form and system do institutions use to submit their annual report?

    Institutions submit Form PHS-6349 through ORI’s Annual Report on Possible Research Misconduct system (ARPRM), which now requires two-factor authentication tied to the institution’s registered email address.

    Implications for research administrators

    The overlap between the Final Rule’s 1 January 2026 effective date and the routine 30 April annual report deadline compresses an already tight compliance calendar. Research integrity officers now need to reconcile three separate obligations in the same window: filing the standard annual report, confirming that institutional policies match the revised regulatory text, and correctly classifying any pending allegation as either a 2005-rule case or a 2026-rule case for procedural purposes.

    ORI’s most recent published Annual Report, covering 2024 activity, recorded 713 allegations of possible research misconduct and 117 new cases opened that year, with 38 cases carried over from prior years — a caseload that gives some sense of scale for institutions weighing how much internal capacity to dedicate to inquiry and investigation infrastructure under the tightened procedural clock.

    • Audit institutional policy language against ORI’s June 2025 Sample Policies and Procedures document before certifying compliance in the 2026 assurance filing.
    • Tag open cases by intake date to determine which regulatory version (2005 or 2026) governs each proceeding.
    • Confirm ARPRM account access and two-factor authentication setup well ahead of the 30 April deadline — do not wait for filing week.
    • Brief institutional review boards and legal counsel on the expanded defined terms, particularly “recklessly” and “intentionally,” which affect how misconduct findings are documented.

    Looking ahead

    The 2026 cycle is likely to be the messiest transition year institutions face under 42 CFR Part 93 for some time: two regulatory regimes running in parallel, a compressed policy-update timeline, and an unchanged annual filing deadline that does not care which rule applies to a given case. Institutions that treat the 30 April 2026 Form PHS-6349 submission purely as a data return — rather than as an opportunity to verify their underlying policies actually match the current regulation — risk finding gaps only when ORI reviews a proceeding. Research administrators tracking related standards work, including contributor-role and authorship frameworks referenced in misconduct findings, can cross-reference CASRAI’s CRediT contributor role and authorship resources when documenting responsibility in a research record.